RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Increased by Bank of New York Mellon Corp

Bank of New York Mellon Corp raised its stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 24.0% during the second quarter, HoldingsChannel reports. The fund owned 114,590 shares of the company’s stock after acquiring an additional 22,175 shares during the quarter. Bank of New York Mellon Corp’s holdings in RAPT Therapeutics were worth $349,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its position in shares of RAPT Therapeutics by 5.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 234,439 shares of the company’s stock worth $5,826,000 after purchasing an additional 12,650 shares during the last quarter. CenterBook Partners LP acquired a new stake in RAPT Therapeutics during the fourth quarter valued at approximately $781,000. Artia Global Partners LP bought a new position in RAPT Therapeutics during the 4th quarter worth approximately $488,000. Octagon Capital Advisors LP bought a new position in RAPT Therapeutics during the 4th quarter worth approximately $7,256,000. Finally, Perceptive Advisors LLC grew its position in shares of RAPT Therapeutics by 11.4% in the 4th quarter. Perceptive Advisors LLC now owns 2,139,950 shares of the company’s stock worth $53,178,000 after acquiring an additional 219,292 shares in the last quarter. 99.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. UBS Group dropped their price target on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research report on Monday, September 9th. HC Wainwright reiterated a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, August 20th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $18.17.

RAPT Therapeutics Stock Performance

Shares of RAPT Therapeutics stock opened at $1.76 on Thursday. The stock has a market capitalization of $61.42 million, a price-to-earnings ratio of -0.57 and a beta of 0.33. RAPT Therapeutics, Inc. has a twelve month low of $1.73 and a twelve month high of $27.35. The business’s 50 day simple moving average is $2.43 and its 200-day simple moving average is $4.63.

RAPT Therapeutics (NASDAQ:RAPT) last issued its earnings results on Thursday, August 8th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.03. Sell-side analysts predict that RAPT Therapeutics, Inc. will post -2.73 earnings per share for the current year.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.